In many types of renal glomerulonephritis, macrostimulated renal macrophage cells.
a role in ischemia and toxic chemical injury within the production.
renal tissue [3].
Methods. IL-6 protein, mRNA, and promoter activity were Among these proinflammatory cytokines, interleukin-6 measured in these cells exposed to LPS (1 g/ml) and/or terbu-(IL-6) is a pleiotropic cytokine that is involved in intaline (10 Ϫ9 to 10 Ϫ6 m). Furthermore, the time course effects of terbutaline on cAMP, MAPK (p42/p44), and TNF-␣ release flammatory and immune responses, acute phase reacwere evaluated in the cells.
tions, and hematopoiesis. At the level of the kidney, IL-6
Results. Terbutaline at high concentrations (10 Ϫ6 m) signifiis a key factor in mediating various components of the cantly up-regulated IL-6 by approximately 25% (P Ͻ 0.05), immune and inflammatory response [4] . For example, whereas at a lower concentration (10 Ϫ8 m), it down-regulated IL-6 can induce the adhesion of circulating cells to the IL-6 production by 42% (P Ͻ 0.05). Terbutaline (10 Ϫ8 and 10 Ϫ6 m) caused a concentration-and time-dependent stimulation of glomerular capillary wall [5] . It can induce proliferation cAMP (P Ͻ 0.05) and TNF production (P Ͻ 0.05) and a timeof mesangial cells [6] and is associated with mesangial dependent decrease in MAPK activity (P Ͻ 0.05). Following proliferative glomerulonephritis [7] . Therefore, there is the addition of a cAMP inhibitor, IL-6 promoter activity was a strong possibility that renal IL-6 generation is one of correlated with TNF-␣ levels and MAPK activity.
the most important initial steps in the pathophysiology
Conclusions. A biphasic effect of ␤ 2 -adrenoceptor agonist on IL-6 production in renal resident macrophage cells became of renal disease and injury [8] .
apparent when LPS was exposed to the cells. The terbutalineThere is increasing evidence that activation of ␤ 2 -adreinduced down-regulation of IL-6 gene production was medinoceptors can modulate the production of lipopolysacated by an inhibitory effect of terbutaline on TNF-␣, which charide (LPS)-induced inflammatory cytokines, such as was exerted through the MAPK and cAMP pathways, whereas the up-regulation appeared to be due to a direct action of tumor necrosis factor (TNF) and IL-1, in some tissues intracellular cAMP. and organs [9, 10] , and Hetier et al have suggested that ␤-adrenoceptor agonists may have an anti-inflammatory influence on the cytokine network during the course of the immunological responses [11] . However, the action of ␤ 2 -adrenoceptor stimulation on IL-6 production is adrenoceptors and the activation of adenylate cyclase assay kit, and isotopes ([␣-32 P]dCTP, [␥-32 P]ATP) were purchased from Amersham Japan (Tokyo, Japan). Un- [12] . It is recognized that intracellular cAMP plays an important role in the stimulation of IL-6 gene expression less stated, reagents were from Sigma Chemical Co. (St. Louis, MO, USA). [13] , and it has been suggested that raised IL-6 production caused by ␤ 2 -adrenoceptor activation is mediated Construction of reporter plasmid through the cAMP pathway. On the other hand, Straub et al demonstrated that isoproterenol inhibited IL-6 seThe IL-6 promoter was amplified using Wistar rat genomic DNA as a template, which was extracted from cretion in the spleen [14] , whereas our own studies also indicated an inhibitory effect of ␤ 2 -adrenoceptor activaspleen using a genomic DNA isolation kit. The amplification profile of the target DNA was performed as foltion following LPS-induced IL-6 gene transcription in rat astrocytes [15] . Furthermore, in an in vivo study, lows: denaturation at 94ЊC for one minute, primer annealing at 55ЊC for one minute, and extension at 72ЊC epinephrine infusion into human subjects did not affect IL-6 production following an LPS challenge [16] . These for two minutes for the first 20 cycles, followed by 30 cycles. For the first polymerase chain reaction (PCR), findings suggest that factors and/or regulatory mechanisms other than the cAMP pathway contribute to ␤ 2 -the upstream primer extended from 1806 to 1825 bp of the rat IL-6 gene [17] , whereas the downstream primer adrenoceptor-mediated IL-6 production. Consequently, the mechanisms by which ␤ 2 -adrenoceptor activation deextended from 3127 to 3146 bp of the rat IL-6. For the second PCR, the upstream primer extended from 2353 termine IL-6 production both normally and in pathophysiological states such as endotoxemia are unclear.
to 2378 bp of the rat IL-6 gene [17] with an engineered restriction for Nhe I at bp 2357, and the downstream This study was designed to examine the regulatory mechanisms involved in the LPS-induced renal IL-6 proprimer extended from 2933 to 2954 bp of the rat IL-6 with an engineered restriction for Hind III at bp 2950. duction following ␤ 2 -adrenoceptor stimulation with terbutaline. Resident renal macrophages were challenged
The amplified product was electrophoresed on a 1% agarose gel, and a discrete band of the expected size with LPS, and the role of ␤ 2 -adrenoceptor-mediated intracellular cAMP in the regulation of IL-6 transcriptional (0.6kb) was isolated from the gel, digested with Nhe I and Hind III, and subsequently cloned into Nhe I-Hind activity was determined. Furthermore, because the rate of IL-6 transcription is also dependent on the generation III of the pGV-B2 (Pica Gene basic vector-2) to generate pGV-B2-IL-6prom. This region contains potential recogof TNF-␣, we examined the effect of ␤ 2 -adrenoceptor stimulation on mitogen-activated protein kinase (MAPK) nition sites for several transcription factors, including the nuclear factor (NF)-B and NF-IL-6, and comparison activity (p42/p44), which, in turn, contributes to the regulation of TNF-␣ production.
of the region with human IL-6 promoter revealed a high degree of conservation. Confirmation of the identity of the insert with the known sequence of the promoter was METHODS obtained by means of restriction mapping and sequencReagents ing. The sequences of these promoters were checked by the cycle sequencing method using an automatic seDulbecco's modified Eagle's medium (DMEM), glutamine, kanamycin, HEPES, antibody against ␤ 2 -adrenoquencer (ABI 377). ceptor, PD098059, and fibronectin were obtained from Renal macrophage cells and culture conditions Cosmo Bio Corp. (Tokyo, Japan). Genomic DNA isolation kits were obtained from GIBCO BRL (Life TechPrimary cultures of resident renal macrophage cells, including glomerular and tubular macrophages, were nologies Inc., Gaithersburg, MD, USA). pGV-B2 (Pica Gene basic vector-2) and cell lysis buffer were from Toyo performed using a modification of the method of Cole and de Vellis [18] . The primary cultures were initiated Inc. Corp. (Tokyo, Japan). Nhe I and Hind III were obtained from Takara Corp. (Shiga, Japan). Fetal bovine from whole kidneys pooled from batches of newborn Wistar rats (day 1 and 2), which were euthanized under serum (FBS) was purchased from Dainippon Pharmaceutical Corp. (Tokyo, Japan). Transfectam was supplied ether anesthesia. The kidneys were dissected and then minced with a razor blade to yield 1 mm 3 fragments, by Bio Sepra Inc. (Marlborough, MA, USA). The luminometer (Lumat LB953AT) was purchased from Berthold which were then resuspended gently in DMEM supplemented with 10% FBS, 10 mm HEPES, l-glutamine (600 (Wildbad, Germany). Isogen was obtained from Nippon Gene (Tokyo, Japan), and ICI 118,551 was obtained mg/liter), and kanamycin (100 g/ml) and were plated into tissue culture flask (75 cm 2 ) precoated with fibrofrom Funakoshi (Tokyo, Japan). ABI 377 was supplied by PE-ABI Corp. (Foster City, CA, USA). Rat TNF-␣ nectin (0.1 mg/ml). The cells were incubated in the flask at 37ЊC in 5% CO 2 . The medium was changed every and IL-6 enzyme-linked immunosorbent assay (ELISA) kits were from Biosource International Inc. (Camarillo, three days, and after two weeks cells growing on top of the confluent fibroblast monolayer were detached by CA, USA). The cAMP ELISA kit, MAPK (p42/p44) overnight shaking. Free cells were collected, and trypan the peptide reflected MAPK activity. Intracellular cAMP was estimated using a commercially available ELISA kit blue was used to assess viability. Cells were replated in in which the assay was based on the competition between 25 cm 2 tissue culture dishes. Macrophage purity was more unlabeled cAMP and a fixed quantity of peroxidasethan 90% as determined by Ia induction by interferon labeled cAMP for a limited number of binding sites on a (IFN)-␥ using antimouse and rat Ia monoclonal antibody cAMP-specific antibody. Cells were lyzed using a liquid-PE conjugate. Furthermore, the cells were identified by phase extraction method, and the supernatants were means of immunostaining using double labeling with ␤ 2 -used for the analysis. adrenoceptor antibody-FITC conjugate. For the study for protein, mRNA accumulation, cAMP, and MAPK Transfection and luciferase assay and assay, the cells (1 ϫ 10 6 ) were incubated for up to 24 experimental protocol hours with serum-free DMEM (5 ml). For the luciferase Transfection of pGV-B2-IL-6prom into the renal macassay, three hours before transfection, the cells at 3 ϫ10 5 rophage cells was performed using a Transfectam kit cells were washed with phosphate-buffered saline, and following the manufacturer's recommendations. The the medium was replaced with fresh medium containing
Transfectam stock solution (15 l) was added to tubes no serum.
containing 500 l of complete serum-free DMEM and vortexed. The pGV-B2-IL-6prom (4 g) and pact ␤-gal Analysis of tumor necrosis factor-␣ and interleukin-6 plasmid (1 g) was constructed and hence contained protein and mRNA ␤-galactosidase activity (gift from Professor M. YamaTo estimate the effect of ␤ 2 -adrenoceptor stimulation moto, The Institute of Medical Science, University of on TNF-␣ and IL-6 mRNA and protein expression, suTokyo, Tokyo, Japan) suspended in 500 l of complete pernatants were removed for TNF-␣ and IL-6 protein serum-free DMEM and vortexed. The DNA and Transassay, and the cells were then collected for IL-6 mRNA fectam stock solutions were immediately mixed and then measurement. Rat TNF-␣ and IL-6 proteins were estiexposed to the cells. The Transfectam/DNA complex mated using ELISA kits according to the manufacturer's was left in contact with the cells for six hours, and then instructions. We estimated mRNA levels using Northern 1 ml of DMEM containing 20% FCS was added to the blot hybridization analysis, as described in our previous dishes for three hours. Cells were maintained in serumstudy [19] . Briefly, total RNA was extracted from the free DMEM for 24 hours prior to the experiments. cells using Isogen according to the manufacturer's inFor the luciferase assay, the cells were incubated for structions. For Northern blot hybridization, the 600 bp one or three hours with serum-free DMEM under the Eco RI/Hind III fragment derived from the cDNA insert following conditions. To investigate the effect of the ␤ 2 -of clone pGEM (a gift from Dr. S. Akira, University of adrenoceptor agonist terbutaline on the transcriptional Osaka) for murine IL-6 and the 420 bp Hinf I fragment activity of the IL-6 gene, terbutaline (10 Ϫ8 or 10 Ϫ6 m) for human ␤-actin (National Children's Research Cenwas added with or without the LPS (1 g/ml) challenge. ter, Tokyo, Japan) were labeled by means of the oligoTo establish whether the effects of terbutaline were melabeling method in the presence of [␣-32 P] dCTP and diated via ␤ 2 -adrenoceptors, the ␤ 2 -adrenoceptor antagoused as a hybridization probe. All mRNA samples (10 nist ICI 118,551 was used. To abolish any action of intrag) were simultaneously applied to a Biodyne A memcellular cAMP, the cAMP inhibitor (H-89, 5 ϫ 10 Ϫ6 m) brane, hybridized and exposed for the same time. The was prepared. To study the effect of cAMP on the tran-␤-actin cDNA probe was used as a loading control after scriptional activity of the IL-6 gene, an analogue of the IL-6 probe was stripped from the membrane.
cAMP, dpcAMP (10 Ϫ7 , 10 Ϫ5 , or 10 Ϫ3 m), was added to the dishes.
Measurement of mitogen-activated protein kinase
The incubated cells were harvested by adding 400 l (p42/p44) and cAMP of lysis buffer [10 mm Tris, 10 mm ethylenediaminetetraMitogen-activated protein kinase was estimated using acetic acid (EDTA), and 150 mm NaCl, pH 8.0] at one a commercial radioimmunoassay kit based on the or three hours after administration. The luciferase p42/p44 MAPK-catalyzed transfer of the ␥-phosphate activity was measured using a luminometer (Lumat group of adenosine 5Ј-triphosphate to a peptide that is LB953AT) and a Pica Gene Luciferase assay system. selective for p42/p44 MAPK. Cells were lyzed in 10 mm
The luciferase activities were normalized on the basis of Tris, 150 mm NaCl, 2 mm EGTA, 2 mm dithiothreitol, ␤-galactosidase activities, which were assayed as de-1 mm orthovanadate, 1 mm phenylmethylsulfonyl fluoscribed previously [15] . The data were expressed as the ride, 10 g/ml aprotinin (pH 7.4) and then centrifuged fold activation, which was calculated by dividing normalat 25,000 ϫ g for 20 minutes. The supernatant was reized luciferase activity (luciferase/␤-galactosidase) in the tained, as it contained the cytoplasmic MAPK. The reaccells by the level of activity in the "control." The experition was initiated by the addition of [␥-32 P] ATP at 30ЊC ments in which transfection was performed simultaneously were run three times. for 30 minutes, and the rate of incorporation of 32 P into Protocol of the study for protein, mRNA accumulation, cAMP, and mitogen-activated protein kinase assay To investigate the time course effect of the ␤ 2 -adrenoceptor agonist on IL-6 and TNF-␣ levels in the supernatant of rat renal resident macrophage cell cultures, we measured supernatant IL-6 and TNF protein levels at 0, 1, 2, 3, 4, 6, and 24 hours after LPS (1 g/ml) challenge and/or terbutaline (Ter 10 Ϫ6 to 10 Ϫ9 m). To determine whether the effects of terbutaline were mediated via ␤ 2 -adrenoceptors, the ␤ 2 -adrenoceptor antagonist (ICI 118,551:ICI) was used. To abolish any action of intracellular cAMP, the cAMP inhibitor (H-89, 5 ϫ 10 Ϫ6 m) was prepared. We estimated IL-6 mRNA levels at 24 hours after LPS (1 g/ml) challenge with or without the addition of terbutaline (Ter 10 Ϫ6 or 10 Ϫ8 m) and measured ence of MAPK (p42/p44) inhibition on IL-6 and TNF-␣ releases from the cells, LPS (1 g/ml) was added to the cells after 20 minutes of pretreatment with MAPK/ terbutaline exerts a biphasic effect on IL-6 production extracellular signal-regulated kinase-1 (MEK-1) inhibithat was dependent on the incubation concentration tor, PD098059 (10 Ϫ5 or 10 Ϫ6 m). IL-6 or TNF-␣ was meawhen the cells were exposed to LPS. When terbutaline sured in the supernatant 24 or 3 hours after the LPS (10 Ϫ6 to 10 Ϫ9 m) alone was given, the IL-6 level at 24 challenge, respectively. hours (terbutaline 10 Ϫ6 m, 21 Ϯ 5 pg/ml; 10 Ϫ7 m, 18 Ϯ 3 Statistics pg/ml; 10 Ϫ8 m, 13 Ϯ 3 pg/ml; 10 Ϫ9 m, 14 Ϯ 5 pg/ml) was not changed compared with control (12 Ϯ 4 pg/ml). Statistical analysis was undertaken using analysis of These findings were supported by observations on the variance followed by the Bonferroni and Dunnet tests level of cellular IL-6 mRNA ( Fig. 2) , in that the LPSor Kruskal Wallis test for multiple comparisons of the induced increase in IL-6 mRNA was significantly (P Ͻ luciferase activity. Results were expressed as mean Ϯ se 0.05) greater in the presence of 10 Ϫ6 m terbutaline but of the mean.
was significantly depressed (P Ͻ 0.05) following the addition of 10 Ϫ8 m terbutaline. Under control conditions, in RESULTS which the cells were exposed to terbutaline but without Effects of ␤ 2 -adrenoceptor stimulation on the LPS challenge, IL-6 mRNA expression was not interleukin-6 production changed. Figure 3 shows the responses in IL-6 promoter activity induced by LPS alone or in combination with Figure 1 shows the time course of LPS on IL-6 protein terbutaline following one and three hour exposures of supernatant levels of macrophage cell cultures alone and the cells. Exposure of the cells for one hour to the LPS in the presence of the ␤ 2 -adrenoceptor agonist terbutaincreased IL-6 promoter activity by approximately 2.7-line. Following three hours of exposure to LPS, there fold, but this was significantly (P Ͻ 0.05) suppressed by was a slight suppression of IL-6 levels, but at 24 hours terbutaline in a concentration-dependent manner. The there was a sharp increase in production of some 45-fold.
addition of terbutaline alone at 10 Ϫ6 and 10 Ϫ8 m did not After a three-hour exposure to the high concentration of change IL-6 promoter activity. Interestingly, three hours terbutaline (10 Ϫ6 m), the increase in IL-6 levels induced after the incubation with LPS, IL-6 promoter activity was by LPS was enhanced, reaching some 57-fold increase increased by approximately 14-fold, but when combined at 24 hours, which was significantly greater than that with the high concentration of terbutaline (10 Ϫ6 m), the achieved with LPS alone (P Ͻ 0.05). By contrast, in the IL-6 promoter activity was significantly (P Ͻ 0.05) encells exposed to the low concentration of terbutaline hanced compared with LPS alone, reaching a 21-fold (10 Ϫ8 m), the LPS-induced increases in IL-6 production rise. Coincubation of LPS plus the low concentration of were attenuated, achieving only a 33-fold increase at 24 hours (P Ͻ 0.05). Together, these data indicate that terbutaline (10 Ϫ8 m) significantly (P Ͻ 0.05) depressed the LPS-induced promoter activity, achieving only a tration. It is clear that dpcAMP stimulated IL-6 promoter ninefold increase. These changes in IL-6 promoter activactivity in a concentration-related fashion, reaching an ity closely corresponded to the pattern of responses obapproximate sixfold (P Ͻ 0.05) stimulation at 10 Ϫ3 m served in the protein and mRNA levels of IL-6. Under dpcAMP. Figure 5 examines the changes in endogenous the conditions in which the LPS challenge was not given, concentration of intracellular cAMP in the cells exposed terbutaline increased IL-6 promoter activity in a doseto LPS alone or together with terbutaline. Terbutaline dependent manner, although by only approximately 70% 10 Ϫ6 and 10 Ϫ8 m significantly (P Ͻ 0.05) increased intra-(10 Ϫ6 m). The increases in IL-6 promoter activity induced cellular cAMP levels in a concentration-dependent manby the LPS plus the terbutaline were abolished using the ner, and the pattern of these responses was unaffected ␤ 2 -adrenoceptor antagonist ICI 118,551, compatible with by the presence of LPS. To further evaluate the contribu-␤ 2 -adrenoceptors mediating these changes in IL-6 protion of intracellular cAMP to the IL-6 promoter activity moter activity in the cells; that is, not only was there induced by terbutaline administration, an inhibitor of potentiation by the high concentration of terbutaline but the cAMP-protein kinase A (PKA) pathway, H-89, was also attenuation by the low concentration of terbutaline.
added to the cells treated with LPS and/or terbutaline; Intracellular cAMP and interleukin-6 the responses are shown in Figure 6 . Following a onepromoter activity hour exposure to H-89, the LPS increased IL-6 promoter activity by some 3.5-to 4-fold, but this response was Figure 4 shows the effect of the cAMP analogue on IL-6 promoter activity in the cells one hour after adminissignificantly (P Ͻ 0.05) attenuated by terbutaline in a Cells were cultured for one hour in the presence or absence of dpcAMP (10 Ϫ7 to 10 Ϫ3 m), after which cytosolic extracts were prepared and used for the luciferase and ␤-gal assays. The fold activation is the ratio of normalized luciferase activity (luciferase/␤-galactosidase) divided by the level of the normalized activity in the untreated cells. Data are the mean Ϯ se from three experiments. *P Ͻ 0.05 vs. cells exposed to dpcAMP (10 Ϫ7 m). ent (Fig. 3) . These findings indicate that the LPS-induced stimulation of IL-6 promoter activity and its modulation by ␤ 2 -adrenoceptor activation seem to involve not only intracellular cAMP but some other factors. Figure 7A shows the time course of action of terbuta- activity at 40 minutes was suppressed. In Figure 7B , the comparisons of MAPK activity at 40 minutes between these groups are shown as bar graphs. Terbutaline (10
Suppression of MAPK (p42/p44) by terbutaline

Ϫ6
and 10 Ϫ8 m) significantly (P Ͻ 0.05) suppressed MAPK concentration-dependent manner by approximately 30 and 55% at 10 Ϫ8 and 10 Ϫ6 m (both P Ͻ 0.05), respectively, activity induced by the LPS. The terbutaline suppression of LPS-induced MAPK activity was abolished by the ␤ 2 -which was similar to the pattern of responses obtained in the absence of H-89 (Fig. 3) . However, at three hours adrenoceptor antagonist ICI 118,551, which was most likely caused by functional ␤ 2 -adrenoceptor activation. in the presence of H-89, the LPS-induced stimulation of IL-6 promoter activity reached some 15-fold but was Suppression of tumor necrosis factor-␣ by terbutaline unaffected by the 10 Ϫ8 m terbutaline and was depressed by 24% (P Ͻ 0.05) in the presence of 10 Ϫ6 m terbutaline. Figure 8 presents the changes in supernatant levels of TNF-␣ in cells treated with LPS alone or in combination Importantly, this pattern of response was very different from the biphasic concentration-response observed in with terbutaline. At one and three hours after exposure to LPS, TNF-␣ levels were stimulated approximately the absence of H-89, as shown in Figure 3 . Exposure of the cells to terbutaline alone had very little influence on 3-and 23-fold, respectively, and these responses were significantly (P Ͻ 0.05) suppressed in a concentration-IL-6 promoter activity after either one or three hours, being comparable to that found when H-89 was not presrelated way by the terbutaline at both time points. How- were exposed to the cAMP inhibitor, H-89 (5 ϫ 10 Ϫ6 m), they were administration are shown as pmol/plate (10 6 cells). Cells were incubated cultured in the presence or absence of terbutaline (10 Ϫ6 m, 10 Ϫ8 m) or in the presence or absence of terbutaline (10 Ϫ6 m, 10 Ϫ8 m) or lipopolysaclipopolysaccharide (LPS; 1 g/ml) for one (A) and three (B) hours, charide (LPS; 1 g/ml) or without any treatment. Means of triplicate after which cytosolic extracts were prepared and used for the luciferase cultures are shown. *P Ͻ 0.05 vs. cells exposed with LPS alone. †P Ͻ and ␤-gal assays. The fold activation is the ratio of normalized luciferase 0.05 vs. cells without any treatment.
activity (luciferase/␤-galactosidase) divided by level of the normalized activity in the untreated cells. Data are the mean Ϯ se from three experiments. *P Ͻ 0.05 vs. cells exposed to LPS alone.
ever, in the cells exposed to terbutaline alone, the TNF-␣ level was not changed at either time point. In Figure 9 , in the presence of the cAMP inhibitor, H-89, LPS-induced significantly (P Ͻ 0.05) decreased IL-6 and TNF-␣ re-TNF-␣ level was significantly suppressed by terbutaline lease from the cells following LPS stimulation (Table 1) . at both time points. The magnitude of the inhibitory Inhibition of the MAPK (p42/p44) pathway resulted in response at three hours was small (terbutaline 10 Ϫ6 m, a block of the increase in IL-6 and TNF-␣ production 22% inhibition) compared with that found when H-89 in the cell. was not present (10 Ϫ6 m, 51% inhibition; Fig. 8 ). Importantly, suppression of TNF-␣ by terbutaline partially in-DISCUSSION volved the cAMP pathway, but it was also influenced by other mechanisms.
Interleukin-6 is a multifunctional cytokine whose activities include stimulation of B-cell differentiation, supSuppression of interleukin-6 and tumor necrosis porting the growth of hybridoma cell lines, and stimulafactor-␣ release by MEK-1 inhibitor tion of acute phase protein production by hepatocytes. It is recognized that IL-6 can be produced by a variety The potential role of the MAPK (p42/p44) in LPS signal transduction on IL-6 and TNF-␣ releases was asof cells, such as T cells, B cells, monocytes, fibroblasts, and endothelial cells [4] , whereas in the kidney, IL-6 is sessed using MEK-1 inhibitor, PD098059. The inhibitor ␤ 2 -adrenoceptor agonists in a biphasic concentrationwas used as a ␤ 2 -adrenoceptor antagonist. Data are the mean Ϯ se from dependent way; that is, at high doses, the production of three experiments. *P Ͻ 0.05 vs. cells exposed to LPS alone.
IL-6 was enhanced, whereas at low doses, it was suppressed. It was evident that this biphasic adrenergic modulation of IL-6 was exerted at the mRNA level, as the produced by mesangial and vascular wall smooth muscle increases in IL-6 mRNA in response to LPS were greater cells [20] . The production of IL-6 can be regulated by at the high concentrations of terbutaline and less at low TNF-␣ and infection, whereas enhanced IL-6 gene exconcentrations of terbutaline compared with that generpression has been observed in autoimmune diseases [4, ated with LPS alone. The question arose as to whether [21] [22] [23] . The renal resident macrophage cells can be actimodulation of the rate of transcription might be responvated by LPS and also produce IL-6, as has become sible for the biphasic response to the ␤ 2 -adrenoceptorevident from the findings of this study, which is compatimediated effect. It was apparent that a complex relationble with the report that IL-6 increases in states of endoship existed, in that following a one-hour exposure to toxemia and may be involved in inducing renal tissue damage [8, 22] .
terbutaline, there was a concentration-dependent sup-mediated by ␤ 2 -adrenoceptors, as they were blocked by the selective antagonist ICI 118,551, it was clear that different mechanisms were coming into play at different times. These findings were intriguing in that ␤ 2 -adrenoceptor activation causes the generation of the second-messenger cAMP and suggested that it might have multiple effects on the rate of transcription of the IL-6 in response to LPS. This issue was addressed by examining the action of cAMP on IL-6 transcriptional activity, and indeed, there was a very clear and sensitive stimulation of the gene by the second messenger. Moreover, it was evident that the ability of the ␤ 2 -adrenoceptor agonist to increase cellular cAMP levels was quite independent of the LPS challenge, again suggesting that the second messenger might be acting in more than one way to influence the IL-6 gene expression. This view was reinforced by the findings of the study using the cAMP inhibitor H-89. The results showed that there was a concentrationrelated inhibition of the LPS stimulation of IL-6 promoter activity, which was markedly different from the biphasic pattern of response, which was evident when the direct effect of cAMP was investigated. Thus, it is clear that when the cells are exposed to LPS, a range of factors and/or other regulatory mechanisms are brought into play, including the cAMP pathway, which would ultimately determine the rate at which transcription of the IL-6 gene would occur.
One important and potent factor that is strongly and specifically induced by LPS is TNF-␣, and its biosynthetic regulation seems to be exerted at several levels. The MAPK signaling pathway, and one of the initial LPSstimulated events is the phosphorylation and activation of the p42/p44 isoforms of MAPK (p42/p44) pathway pathway diminished LPS-induced IL-6 mRNA and IL-6 a P Ͻ 0.05 vs. LPS production in liver Kupffer cells. The findings of this study extended these observations and demonstrated that ␤ 2 -adrenoceptor activation suppressed MAPK (p42/ p44) pathway in the cells, which, in turn, was correlated pression in the IL-6 promoter activity to LPS, but at three hours, there was an enhanced response at the high with a decreased TNF-␣ levels and reduction in IL-6 production. Vanden-Berghe et al indicated that the NF-B and a depressed response at the low concentration of terbutaline. Although both patterns of responses were was involved in the regulation of IL-6 gene expression by TNF-␣ [28] . Following a one-hour exposure to terbucAMP and/or MAPK (p42/p44) pathways. Furthermore, other mechanisms and intracellular signals may be also taline, the LPS-induced IL-6 promoter activity was suppressed and correlated with the decreases in MAPK acinvolved with the modulation of LPS-induced IL-6 production by ␤ 2 -adrenoceptor activation. tivity and TNF-␣. The effect of terbutaline on IL-6 promoter activity was not influenced by the addition of H-89, which would suggest that the decrease in LPS-ACKNOWLEDGMENTS induced IL-6 promoter activity observed at one hour tion and IL-6 production [30] . This suggests that the tumor necrosis factor. cAMP pathway leads to an inhibition of TNF levels, which indirectly would decrease IL-6 production, whereas a REFERENCES direct action of the intracellular cAMP would be to in-
